Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses: 2016-2024

Historic Other Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $1.6 million.

  • Rocket Pharmaceuticals' Other Accumulated Expenses fell 3.50% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3.50%. This contributed to the annual value of $1.6 million for FY2024, which is 8.30% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Other Accumulated Expenses of $1.6 million as of FY2024, which was down 8.30% from $1.8 million recorded in FY2023.
  • Rocket Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $2.3 million during FY2022, with a 5-year trough of $482,000 in FY2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.8 million (2023), whereas its average is $1.9 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Other Accumulated Expenses plummeted by 42.28% in 2021, and later surged by 371.58% in 2022.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Other Accumulated Expenses stood at $835,000 in 2020, then plummeted by 42.28% to $482,000 in 2021, then skyrocketed by 371.58% to $2.3 million in 2022, then dropped by 22.04% to $1.8 million in 2023, then declined by 8.30% to $1.6 million in 2024.